WO2018233213A1 - 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂 - Google Patents

一种治疗恶性肿瘤的中药组合物、制备方法及其制剂 Download PDF

Info

Publication number
WO2018233213A1
WO2018233213A1 PCT/CN2017/113242 CN2017113242W WO2018233213A1 WO 2018233213 A1 WO2018233213 A1 WO 2018233213A1 CN 2017113242 W CN2017113242 W CN 2017113242W WO 2018233213 A1 WO2018233213 A1 WO 2018233213A1
Authority
WO
WIPO (PCT)
Prior art keywords
selected amount
remove
glutinous rice
chinese medicine
medicine composition
Prior art date
Application number
PCT/CN2017/113242
Other languages
English (en)
French (fr)
Inventor
邓圣平
Original Assignee
邓圣平
程韵
赵晓军
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 邓圣平, 程韵, 赵晓军 filed Critical 邓圣平
Publication of WO2018233213A1 publication Critical patent/WO2018233213A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • A61K36/424Gynostemma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536Prunella or Brunella (selfheal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/83Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches

Definitions

  • the present invention relates to a traditional Chinese medicine composition, in particular to a pharmaceutical composition for treating a malignant tumor, and to a preparation method of the traditional Chinese medicine composition and a preparation thereof.
  • a malignant tumor is now called a cancer, and it is a benign tumor.
  • Cancer is a disease caused by the loss of normal regulation and excessive proliferation of the body cells, often manifested as a local mass formed by abnormal proliferation of local tissue cells. Hyperproliferative cells are called cancer cells. Cancer cells can often invade surrounding tissues (invasion), and can even metastasize to other parts of the body through the circulatory system and/or lymphatic system in the body. There are many types of cancer, and the severity of the condition depends on where the cancer is located and whether the degree of malignancy has metastasized. Once confirmed, it is often treated in combination with surgery, chemotherapy and radiation. If the cancer is left untreated, in general the end result will result in death.
  • Cancer is a large class of diseases caused by multiple, multi-stage and multiple mutations in normal cells.
  • the causes of cancer include: environmental pollution, chemical pollution (chemical toxins), ionizing radiation, free radical toxins, microorganisms (bacteria, fungi, viruses, etc.) and their metabolic toxins, genetic characteristics, endocrine imbalance, immune dysfunction.
  • chemical pollution chemical pollution
  • free radical toxins free radical toxins
  • microorganisms bacteria, fungi, viruses, etc.
  • metabolic toxins genetic characteristics, endocrine imbalance, immune dysfunction.
  • cancer is not currently a clear hereditary disease, there is increasing evidence that cancer does have a genetic predisposition, especially in the liver.
  • genes are the material basis for affecting cancer genetics.
  • one is called a proto-oncogene and the other is a tumor suppressor gene.
  • Proto-oncogenes also known as oncogenes, can cause genetic disorders if they are mutated. Under normal and external factors, normal cells become cancer cells; The gene can inhibit or antagonize the function and function of the oncogene. If the tumor suppressor gene is directly mutated, it can also cause cell growth disorder and canceration. Therefore, proto-oncogenes and tumor suppressor genes can be said to be opposite genes. If one of the protooncogenes or tumor suppressor genes conflicts, cancer may occur, which is also a potential factor leading to the hereditary nature of cancer;
  • Chemical factors This is the main cause of malignant tumors that are currently found. At present, more than 1,000 kinds of chemical substances have been found to be carcinogenic in the medical community. Among them, there are more than 30 kinds of closely related to human malignant tumors, such as 3.4-benzopyrene polycyclic aromatic hydrocarbons, mustard gas, benzidine, aniline, Azo compounds, nitrosamine compounds, chromium, nickel, zinc, cadmium, arsenic, molybdenum, rods, cotton, vinyl chloride, benzene, etc., are common carcinogens; some chemicals have potential carcinogenic effects on humans.
  • Biological carcinogenic factors can be divided into two types, one is the virus, and the other is the mold; some viruses lurk into the human body, under certain conditions, it will induce malignant tumors.
  • Malignant tumors related to viruses mainly include nasopharyngeal carcinoma, cervical cancer, leukemia, and liver cancer.
  • the grains, nuts and vegetables that we eat in our daily life are easily contaminated by various molds such as koji toxin, Fusarium, Alternaria, and Aspergillus, resulting in the induction of liver cancer and gastric cancer;
  • HPV human papillomavirus factor HPV human papillomavirus is generally benign, once caused by lesions, can also cause respiratory papilloma (respiratory papillomatosis) and each Other cancers;
  • Lifestyle effects Studies have shown that poor lifestyles do have a positive impact on cancer pathologies such as smoking, diet, exercise, alcohol, sun exposure, and sexually transmitted diseases.
  • the occurrence of cancer is also related to the amount of melatonin in the body. When it takes a long time to stay in a bright environment, the melatonin expression will be low, and the incidence of cancer is higher;
  • Diffusion effect Although the tumor can temporarily solve the problem of self-cultivation by building blood vessels during its growth, the rapid growth will push it to the edge of resources and space shortage. At this time, the tumor will spread and begin to invade the surrounding area. Normal tissue (cancer infiltration) and transfer to the distal end (cancer metastasis) by blood vessels.
  • the main means of treating cancer relies on Western medicine, often in combination with surgery, chemotherapy and / or radiotherapy.
  • the above treatment method can also damage healthy cells while killing cancer cells. Patients also need to suffer from the pain and adverse side effects caused by surgery, chemotherapy and radiotherapy. Therefore, Western medicine treatment generally has a low rate of treatment and easy recurrence. The problem is also the problem of higher medical expenses.
  • the treatment of malignant tumors with Chinese medicine has gradually attracted medical attention. Due to its small side effects and low cost of treatment, Chinese medicine has been increasingly applied in clinical practice and has achieved good results.
  • the technical problem to be solved by the present invention is to provide a traditional Chinese medicine composition for treating malignant tumors, and further discloses a preparation method thereof.
  • the present invention provides a traditional Chinese medicine composition for treating a malignant tumor, wherein the raw material medicine composition of the Chinese medicine composition is:
  • the raw material composition of the traditional Chinese medicine composition is:
  • the raw material composition of the traditional Chinese medicine composition is:
  • the invention also discloses a clinically acceptable preparation prepared from the traditional Chinese medicine composition for treating malignant tumor by adding a conventional auxiliary material according to a conventional process.
  • the formulation comprises a capsule, granule, patch, injection, mixture or pill.
  • the auxiliary material includes at least one of medical starch, lactose, ⁇ -cyclodextrin, magnesium stearate, camellia oil, salicylic acid, white petrolatum, glacial acetic acid, solid paraffin, honey, quicklime, and distilled water.
  • the invention also discloses a method for preparing the preparation, which comprises taking a selected amount of camptotheca acuminata, Brucea javanica oil, cantharidin, stellera chamaejasme, Fritillaria, swollen wind, Prunella vulgaris, Rhizoma Curcumae, Radix Scutellariae, Radix Salviae Miltiorrhizae , Sanqi, mulberry, dandelion, Gynostemma pentaphyllum, licorice and tea blending steps, and adding conventional excipients, according to the conventional process of clinically acceptable preparations.
  • the method of preparing the preparation comprises the steps of:
  • S1 take the selected amount of spotted glutinous rice and glutinous rice in a hot pot, heat with a simmer, stir fry until the glutinous rice is yellow-brown, take out, remove the glutinous rice, let cool, remove the scorpion, remove the wings, go to the foot, spare;
  • the mass ratio of the added cantharidin to the glutinous rice is 1:2; in the step S2, the mass ratio of the wolfberry tablet to the rice vinegar is 10:3.
  • the preparation method comprises the following steps:
  • S1 take the selected amount of spotted glutinous rice and glutinous rice in a hot pot, heat with a simmer, stir fry until the glutinous rice is yellow-brown, take out, remove the glutinous rice, let cool, remove the scorpion, remove the wings, go to the foot, spare;
  • the mass ratio of the added honey to the sum of the traditional Chinese medicine raw materials is (3-6):100.
  • the invention also discloses a patch for treating malignant tumor, the raw material composition of the patch is:
  • camptotheca 1-30 parts by weight of Brucea javanica 0.1-0.9 parts by weight
  • the invention also discloses a method for preparing the therapeutic malignant tumor patch, comprising the following steps:
  • S1 take the selected amount of spotted glutinous rice and glutinous rice in a hot pot, heat with a simmer, stir fry until the glutinous rice is yellow-brown, take out, remove the glutinous rice, let cool, remove the scorpion, remove the wings, go to the foot, spare;
  • step S4 take the lime into the container filled with clean water, and obtain lime water after the reaction. After the lime water is cleared for 15 days, remove the clear lime water, put it in the container for use, and take the selected amount of Brucea oil and raw Camellia oil, added to a lime water container, stirred into a paste, and finally added to step S3 Prepare a fine powder to make a clinically acceptable patch.
  • the mass ratio of the quicklime to the fresh water added in the step S4 is 1:5, and the mass ratio of the extracted clear lime water to the camellia oil is 1:1.
  • the traditional Chinese medicine composition of the invention is under the guidance of the traditional Chinese medicine theory, and combined with the research results of modern medicine, on the basis of a large number of preliminary experimental research, the seventeen flavor Chinese medicine raw materials are re-assembled.
  • the traditional Chinese medicine composition of the present invention is mainly composed of camptotheca, Brucea javanica, cantharidin, and Stellera chamaejasme, and is mainly used for viciousness; and Fritillaria, swollen wind, Prunella vulgaris, Rhizoma Curcumae, Radix Astragali, Radix, Radix, Radix , mulberry yellow, dandelion, this ten-flavored medicine is a drug, to achieve the effect of clearing away heat and detoxification, promoting blood circulation and removing blood stasis; using Gynostemma pentaphyllum, licorice, tea as a medicine, playing the role of detoxification and poisoning, and correcting evil spirits. among them,
  • camptothecin can cause cancer cells to undergo degeneration, necrosis, nuclear pyknosis, Contamination, chromatin condensation, cytoplasmic vacuoles and other morphological changes can also cause changes in the ultrastructure of cancer cells and host hepatocytes, ultimately leading to the destruction of cancer cells and promote cell death;
  • Brucea It is bitter, cold, has the effect of clearing away heat and relieving phlegm, detoxifying and killing insects. It has anti-tumor effect.
  • Brucea javanica contains a lot of fatty acids, especially unsaturated fatty acids, so it has obvious anti-cancer effect, Brucea javanica, Many different components, such as Brucea javanica, Brucea javanica, Brucea sinensis, Brucea javanica oil, have different degrees of anti-tumor effect, and the most obvious effect of Brucea javanica oil, Brucea javanica, Brucea javanica and Brucea javanica Glycoside A, D, E to P388 lymphocytes, leukemia DNA polymerase, RNA polymerase, thymidylatesyn-thetase, dihydrofolate reductase, phosphoribosyl pyrophosphate aminotransferase and tissue Protease activity has marginal inhibition, inhibiting RNA and protein synthesis.
  • cantharidin is the active ingredient of cantharidin, has strong affinity for liver and cancer cells Cantharidin can first inhibit the protein synthesis of cancer cells, which in turn affects RNA and DNA synthesis, and ultimately inhibits the growth and division of cancer cells;
  • Stellera chamaejasme taste bitter, spicy, flat, has the effect of breaking the water, destroying the insecticide, Gneedi in the wolf's poison has a strong inhibitory effect on a variety of tumors;
  • Fritillaria taste bitter, cool, return to the lungs, stomach, anti-cancer effect, soil fritillaria I has a inhibitory effect on a variety of transplanted tumors, the effect of clearing away heat and phlegm, loosening and detoxification;
  • Swollen wind bitter taste, flatness, hurricane dehumidification, promoting blood circulation and dispelling phlegm, clearing away heat and detoxifying effect, swollen wind volatile oil, inoculation on self-blood 615 cells, TM755, lung adenosis 615, white hair breast cancer 615 Spontaneous ascites type AL771, Ehrlich ascites carcinoma, sarcoma 180, sarcoma 37, Wacker cancer 256 have a certain inhibitory effect;
  • Prunella vulgaris bitter, pungent, cold, has the effect of clearing the liver and purging fire, relieving stagnation and dissipating, reducing swelling and detoxification.
  • the ursolic acid contained in Prunella vulgaris has significant effects on cells P388, L1210 and human tumor cells A-549. Cytotoxicity, inhibition of Ehrlich ascites tumor and sarcoma S180;
  • Astragalus membranaceus sweet, mild, warm, qi, sun, solid, antiperspirant, water swelling, anti-tumor effect, anti-tumor effect, Astragalus polysaccharides have synergistic effect on cancerous ascites lymphocyte activation CTL cells in cancerous ascites are easily activated by IL-2, and the activation time is shortened and the amplification factor is large.
  • the peripheral blood mononuclear cells of normal people and tumor patients can significantly promote the secretion of TNF in vitro. Both TNF-a and TNF-b have enhanced effects.
  • Astragalus can significantly enhance the in vitro killing activity of lung cancer infiltrating lymphocytes (TIL), and synergistic positive regulation of TIL cells in combination with ginsenosides;
  • Tanshinone IIA can affect oncogene expression and DNA polymerase activity inhibits HL-60 cell synthesis, thereby inhibiting cell proliferation and inducing cell differentiation;
  • sweet, light, and flat, beneficial to water and spleen, spleen and tonifying, and calming the nerves. It enhances the immune function of the body, activates the immune surveillance system, enhances the body's immunity to cancer-specific antigens, and exerts the body's ability to fight cancer, allowing the activated complement to pass through. Lymphocytes and humoral factors, etc., synergistically kill tumor cells;
  • Sanqi sweet, slightly bitter, warm, has the effect of stopping bleeding and dispersing phlegm, reducing swelling and setting pain, and has anti-tumor effect.
  • the ginseng glycoside Rb1, Rd, Rh1 and Rh2 in Sanqi can make the cultured tumor cells receive Inhibition, Rh1 acts directly on the cell membrane, and Rh2 can re-differentiate the cancer cells to induce reversal into non-cancer cells;
  • Mulberry yellow tastes slightly bitter, cold, has anti-cancer effect, strengthens immunity, induces cancer cells to die by themselves, and can inhibit the proliferation and metastasis of cancer cells;
  • Gynostemma sweet, warm, has the effect of tonic and moistening dryness, phlegm and blood circulation, swelling and detoxification, anti-tumor effect, Gynostemma can prevent normal cell cancer, and promote cells to self-healing ability, guide cancer cell recovery normal.
  • Gynostemma pentaphyllum has a significant effect on the CO irradiation effect of human gastric adenocarcinoma (SGC-7901) cells, showing an increase in cell survival rate, a significant increase in S phase cells, and a decrease in the proportion of cells in G1 and G2 phases; Gynostemma pentaphyllum, Gynostemma x, X can be Directly kill the tumor cells in S180.
  • SGC-7901 human gastric adenocarcinoma
  • Gynostemma saponin XX1 significantly inhibited the growth of liver cancer cells in vitro.
  • Gynostemma saponins have inhibitory effects on lung cancer, uterine cancer and melanoma tumor cells cultured in vitro.
  • Ginseng diol and protopanaxadiol in Gynostemma pentaphyllum have certain anti-tumor activity, and Gynostemma pentaphyllum polysaccharide has strong inhibitory effect on tumor cells.
  • Gynostemma inhibits tumor cells, proliferates and enhances immune function, mainly in the blockade of mitotic cancer cells, interfering with DNA synthesis and improving its ability to mutate.
  • GPS can significantly increase the frequency of sister chromosome exchange caused by cyclophosphamide.
  • Gynostemma can reduce the DNA synthesis of rectal adenocarcinoma cells, reduce the number of nuclear divisions, and degenerate and necrosis of cells;
  • Licorice sweet, flat, beneficial to Qizhongzhong, relieve pain, lungs and cough, purging fire and detoxification, reconcile the drug effect;
  • Tea bitter, sweet, cool, has the advantage of eliminating the head, in addition to annoying quenching thirst to eliminate phlegm, diuretic detoxification, anti-tumor, anti-mutagenic effect, green tea polyphenols (GTP) can inhibit aflatoxin B (AFB) and phenylpropanoid BP, etc., regulate immune function, green tea can improve the bone marrow hematopoietic function damaged by cyclophosphamide, increase the number of white blood cells and red blood cells, and have a genetic regulation effect.
  • GTP green tea polyphenols
  • ARB aflatoxin B
  • phenylpropanoid BP phenylpropanoid BP
  • the traditional Chinese medicine composition of the present invention performs clinical experiments on 56 confirmed patients with advanced primary liver cancer, and the symptoms are completely relieved in 12 cases, partially relieved in 20 cases, stable in 22 cases, and the total effective rate is as high as 96.4. %, indicating that the medicament of the present invention can effectively control the growth of tumors, inhibit the spread of cancer cells, and at the same time improve the symptoms of liver pain, body weakness, loss of appetite, etc., thereby improving the quality of life of patients and prolonging the survival of patients.
  • the medicament of the present invention is used for rehabilitation of lung cancer, lymphoma, gastric cancer, esophageal cancer, bladder cancer, ovarian cancer, prostate cancer, pancreatic cancer and other tumor diseases, and for patients who have undergone surgery, radiotherapy and chemotherapy. It also has the ideal therapeutic effect.
  • S1 take the spotted glutinous rice and glutinous rice according to the mass ratio 1:2, set in a hot pot, heat with a simmer, stir fry until ⁇
  • the rice is yellow-brown, removed, removed from the glutinous rice, let cool, remove the scorpion, remove the wings, and go to the feet for spare;
  • step S4 6g of raw honey is placed in a porcelain pot until it can be 2-3 cm of wire by hand. Add 9g of Brucea javanica oil, mix well, add the powder prepared in step S3, mix and let cool, and obtain Treating malignant tumors with oral honey pills.
  • step S4 7g of raw honey is placed in a porcelain pot until it can be 2-3 cm of wire by hand.
  • step S4 5g of raw honey is placed in a porcelain pot until it can be 2-3 cm of wire by hand.
  • 1.1 Drugs Weighing 12g of Camptotheca acuminata, 0.8g of cantharidin (made), 10g of Wolf's Poison (made), 6g of Fritillaria, 6g of swollen wind, 12g of Prunella vulgaris, 9g of Radix Paeoniae, 9g of Radix Scutellariae, 9g of Radix Scutellariae, 8g of Salvia miltiorrhiza Bge.
  • liver cancer HepS22 liver cancer
  • mice The tumor-bearing passaged mice were sacrificed by cervical dislocation, the skin was cut, and the tumor was selected to grow well without necrosis or The liquefied cancer tissue was added to sterile physiological saline at 1:3, and a suspension of cancer cells was prepared with a tissue homogenizer, and 0.2 ml of the experimental mice were inoculated subcutaneously. Randomly grouped the next day after inoculation, 12 in each group.
  • Three experimental groups, a model group and a control group were administered at high, medium and low doses.
  • the high-dose experimental group was administered at a dose of 1 g/kg body weight
  • the medium-dose experimental group was administered at a dose of 0.5 g/kg body weight
  • the low-dose experimental group was administered at a dose of 0.1 g/kg body weight.
  • the control group was given cyclophosphamide 20 mg/kg body weight.
  • the model group was given sterile saline 1 g/kg body weight.
  • the drug was administered by intragastric administration once a day for 10 days after administration.
  • Tumor inhibition rate (1 - average tumor weight of the drug-administered group / mean tumor weight of the model group) ⁇ 100%.
  • the data were analyzed by SPSS17.0 software.
  • the measurement data were expressed by X ⁇ S.
  • the t-test was used to compare the indicators before and after treatment.
  • the X2 test was used for the counting data. P ⁇ 0.05 indicates that the difference is statistically significant.
  • mice Average tumor weight (g) X ⁇ SD Tumor inhibition rate (100%)
  • Model group 12 3.14 ⁇ 0.16 - Control group 12 1.57 ⁇ 0.21 50.00
  • High dose group 12 1.44 ⁇ 0.28 54.14
  • Medium dose group 12 1.56 ⁇ 0.32 50.32
  • Low dose group 12 1.68 ⁇ 0.44 46.50
  • the experimental results show that the traditional Chinese medicine composition of the invention has obvious inhibitory effect on experimental liver tumor in mice.
  • the anti-tumor rate of the high-dose group of the traditional Chinese medicine composition of the invention is significantly higher than that of the western medicine cyclophosphamide control group. And there are significant differences.
  • the 56 patients selected in this study were all diagnosed patients with advanced primary liver cancer, all of which met the diagnostic criteria associated with primary liver cancer in the Guidelines for Clinical Diagnosis and Treatment.
  • 33 were male and 23 were female, with an average age of 44 years.
  • Clinical stage 35 cases in stage II, 21 cases in stage III.
  • Stable less than 25% of tumor tissue shrinkage or enlargement
  • Tumor tissue enlargement is greater than 20%.
  • Improvement of clinical symptoms the improvement rate of pain in the liver area was 82.5%, the improvement rate of fatigue inability was 76.9%, and the improvement rate of loss of appetite was 83.2%.
  • Therapeutic effect complete remission in 12 cases, accounting for 21.4% of the total number of cases; partial remission in 20 cases, accounting for 35.7% of the total number of cases; stable in 22 cases, accounting for 39.3% of the total number of cases; worsening in 2 cases, accounting for the total number of cases 3.6%.
  • the total effective rate was 96.4%.
  • the experimental results show that the traditional Chinese medicine composition of the invention can effectively control the growth of the tumor, inhibit the spread of the cancer cells, and at the same time improve the symptoms of pain, body weakness and loss of appetite in the liver area of the patient, thereby High patient quality of life and prolong patient survival.
  • the medicament of the present invention is similar to other tumor diseases such as lung cancer, lymphoma, gastric cancer, esophageal cancer, bladder cancer, ovarian cancer, prostate cancer, pancreatic cancer, and the rehabilitation of tumor patients who have undergone surgery, radiotherapy, and chemotherapy. Have the ideal therapeutic effect.
  • Example 1 of the present invention Using the capsule prepared in Example 1 of the present invention to treat 32 patients with gastric cancer after 3-6 courses of treatment, the therapeutic effect of the 32 patients with gastric cancer was observed, 18 cases were cured, 8 cases were markedly effective, and improved. 5 cases, 1 case was invalid, and the total effective rate was 96.9%.
  • Example 2 of the present invention Using the granules prepared in Example 2 of the present invention to treat 29 patients with lung cancer after 3-5 courses of treatment, the therapeutic effect of the 29 patients with lung cancer was observed, of which 22 cases were cured, 5 cases were markedly effective, and improved. In 1 case, 1 case was invalid, and the total effective rate was 95.5%.
  • Example 2 of the present invention Using the granules prepared in Example 2 of the present invention to treat 25 patients with bladder cancer, the therapeutic effect of the 25 patients with bladder cancer was observed after 3-5 courses of treatment, among which 14 cases were cured and 6 cases were markedly effective. 3 cases were improved, 2 cases were ineffective, and the total effective rate was 92.0%.
  • Example 2 of the present invention Using the granules prepared in Example 2 of the present invention to treat 18 patients with ovarian cancer after 3-5 courses of treatment, the therapeutic effects of the 18 patients with ovarian cancer were observed, of which 11 cases were cured and 3 cases were markedly effective. 3 cases were improved, 1 case was ineffective, and the total effective rate was 94.4%.
  • Example 3 of the present invention Using the patch prepared in Example 3 of the present invention to treat 16 patients with prostate cancer after 3-5 courses of treatment, the therapeutic effect of the 16 patients with prostate cancer was observed, among which 10 cases were cured and 2 cases were markedly effective. 4 cases improved, 0 cases were ineffective, and the total effective rate was 100%.
  • Example 4 of the present invention Using the oral large honey pill prepared in Example 4 of the present invention to treat 30 patients with esophageal cancer after 3-6 courses of treatment, observe the therapeutic effect of the 30 patients with esophageal cancer, of which 8 cases were cured, markedly effective In 7 cases, 3 cases were improved and 2 cases were ineffective. The total effective rate was 93.3%.
  • Example 7 After treating 3 patients with lymphoma in 3-6 courses of treatment with the traditional Chinese medicine compound prescription prepared in Example 7 of the present invention, the therapeutic effects of the 23 patients with lymphoma were observed, 14 cases were cured, and 4 cases were markedly effective. For example, 3 cases were improved and 2 cases were ineffective. The total effective rate was 91.1%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Insects & Arthropods (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种治疗恶性肿瘤的中药组合物、其制备方法及其制剂,所述中药组合物的原料药组成为喜树果、鸦胆子油、斑蝥(制)、狼毒(制)、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草、茶叶。

Description

一种治疗恶性肿瘤的中药组合物、制备方法及其制剂 技术领域
本发明涉及一种中药组合物,特别涉及用于治疗恶性肿瘤的药物组合物,本发明还涉及该中药组合物的制备方法及其制剂。
背景技术
恶性肿瘤现称为癌症(cancer),和它相对的是良性肿瘤。癌症是由于机体细胞失去正常调控,过度增殖而引起的疾病,常表现为局部组织的细胞异常增生而形成的局部肿块。过度增殖的细胞称癌细胞,癌细胞常可侵犯周围组织(浸润,invasion),甚至可经体内循环系统和/或淋巴系统转移到身体其他部位,即为癌症转移。癌症有多类型,而病症的严重程度取决于癌细胞所在部位,恶性程度是否发生转移。一旦确认,当今常以结合手术、化疗和放疗的方式进行治疗。如果癌症未经治疗,一般来讲最终结果将导致死亡。
癌症是机体正常细胞在多原因、多阶段与多次突变所引起的一大类疾病。通常来讲癌症的病因包括:机体在环境污染、化学污染(化学毒素)、电离辐射、自由基毒素、微生物(细菌、真菌、病毒等)及其代谢毒素、遗传特性、内分泌失衡、免疫功能紊乱等等各种致癌物质,以及致癌因素的作用下导致身体正常细胞发生癌变的结果。具体而言:
遗传因素:癌症虽然目前不是明确的遗传性疾病,但是越来越多的证据表明,癌症确实有遗传倾向,特别是肝部有关癌症遗传的证据较多。研究表明,基因是影响癌症遗传的物质基础。正常人体内的基因中,有一类叫原癌基因,另一类叫抑癌基因。原癌基因也称为癌基因,如果发生突变,可以导致遗传失调,在内外因素的作用下,使正常细胞变成癌细胞;抑癌 基因能抑制或拮抗癌基因的功能及作用,若抑癌基因直接发生突变,也可导致细胞生长失调而发生癌变。所以说,原癌基因和抑癌基因可以说是对立统一的基因,如果原癌基因或者抑癌基因两者之一发生冲突,就有可能发生癌症,这也是导致癌症遗传性的一个潜在因素;
化学因素:这是目前发现的导致恶性肿癌发生的主要原因。目前医学界已经发现1000多种化学物质具有致癌作用,其中与人类恶性肿癌关系比较密切的有三十余种,比如,3.4-苯并芘类多环芳香烃、芥子气、联苯胺、苯胺、偶氮化合物、亚硝胺化合物、铬、镍、锌、镉、砷、钼、杆、棉、氯乙烯、苯等,均是常见的致癌物质;还有一些化学物质对人类有潜在的致癌作用,比如农药、家庭用化学清洁剂、消毒剂等;另外,研究表明,某些医用药物,如免疫抑制剂、激素类药物等亦有致癌活性。不同的化学物质会引发不同的恶性肿瘤,比如长期大剂量接触铬可引发肺癌,而镍接触则会引起肺癌和鼻咽癌,砷接触则会引发皮肤癌和肝癌,镉接触可引发前列腺癌,3.4--苯并芘则主要食于煤烟灰和煤焦油中,易引发阴囊癌和皮肤癌;
物理因素:研究显示,对人类和动物有致癌作用的主要有电离辐射、X线、微波、电磁波、放射性物质、热辐射、日光、紫外线、机械性刺激、灼热、创伤等。人类受电离辐射易患白血病、骨肉瘤、甲状腺癌等症,较大剂量的X线接触或受大剂量紫外线照射,可诱发皮肤鳞状细胞癌,长期接触放射性物质或长期生活在放射性物质污染区域,容易得肺癌和白血病,长期食用过热,过硬食物易诱发食管癌;
生物因素:生物致癌因素可分为两种,其一是病毒,其二是霉菌;有些病毒潜伏到人体后,在一定条件下,就会诱发恶性肿瘤。与病毒有关的恶性肿瘤主要有鼻咽癌、宫颈癌、白血病、肝癌等。我们日常生活中食用的谷物、坚果和蔬菜等易受曲毒素、镰刀菌、交链孢菌和杂色曲霉菌等多种霉菌的污染,导致诱发肝癌和胃癌;
HPV人类乳头瘤病毒因素:HPV人类乳头瘤病毒一般都是良性的,一但引起病变,也会引起呼吸道乳头状瘤(respiratorypapillomatosis)及各 种其他癌症;
生活方式影响:研究表明,不良的生活方式对癌症病变确实有一定影响,例如吸烟、饮食、运动、酒精、晒太阳以及性病等。癌症的发生也和体内褪黑激素的量相关,当需要长时间待在明亮的环境下,褪黑激素表现量会偏低,而癌症的发病率则较高;
扩散影响:肿瘤在其生长过程中,虽然能够暂时通过搭建血管解决自身给养问题,但是快速的增长一样会将之推向资源和空间匮乏的边缘,这时肿瘤就会扩散,并且开始入侵周围的正常组织(癌症浸润),并且通过血管转移到远端(癌症转移)。
目前,治疗癌症的主要手段依靠西医,常以结合手术、化疗和/或放疗的方式进行治疗。但上述治疗方式在杀除癌症细胞的同时,也会损伤健康细胞,患者还需经受手术、化疗、放疗带来的痛苦及不良副作用,所以西医治疗普遍存在着治逾率较低、以及易复发的问题,另外也存在着医疗费用较高的问题。几年来,以中医疗法治疗恶性肿瘤逐渐引起医学重视,中医疗法因其副作用小且治疗费用较低的优势,正在临床上日益应用,并取得较好的疗效。
发明内容
本发明所要解决的技术问题在于提供一种治疗恶性肿瘤的中药组合物,并进一步公开其制备方法。
为了解决上述技术问题,本发明提供了一种治疗恶性肿瘤的中药组合物,所述中药组合物的原料药组成为:
Figure PCTCN2017113242-appb-000001
Figure PCTCN2017113242-appb-000002
优选的,所述中药组合物的原料药组成为:
Figure PCTCN2017113242-appb-000003
更优的,所述中药组合物的原料药组成为:
Figure PCTCN2017113242-appb-000004
本发明还公开了由所述的治疗恶性肿瘤的中药组合物,添加常规辅料,按照常规工艺制备成的临床可接受的制剂。
更优的,所述制剂包括胶囊剂、颗粒剂、贴剂、针剂、合剂或丸剂。
所述辅料包括医用淀粉、乳糖、β环糊精、硬脂酸镁、山茶油、水杨酸、白凡士林、冰醋酸、固体石蜡、蜂蜜、生石灰、蒸馏水中的至少一种。
本发明还公开了一种制备所述制剂的方法,包括取选定量的喜树果、鸦胆子油、斑蝥、狼毒、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀的步骤,并添加常规辅料,按照常规工艺制成的临床可接受的制剂。
更优的,所述制备所述制剂的方法,包括如下步骤:
S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、鸦胆子油、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,添加常规辅料,按照常规工艺制成的临床可接受的制剂。
所述步骤S1中,加入的斑蝥与糯米的质量比为1:2;所述步骤S2中,加入的狼毒片与米醋的质量比为10:3。
最优的,所述制备方法,包括如下步骤:
S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,加水浸泡后,加热至沸腾并煎煮,取煎煮液加入选定量的鸦胆子油混匀,固液分离后,收集滤液文火浓缩至比重为1.30-1.35的浓缩液,烘干并加入常规辅料,制得临床可接受的胶囊剂;或者,
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,粉碎成粗颗粒状,加水浸泡后,加热煎煮并收集煎煮液,随后加入选定量的鸦胆子油,文火蒸发至比重为0.9-1.1的蒸发液,冷却后加入60wt%乙醇充分混匀沉降,取上清液并减压回收乙醇,浓缩至比重为1.2-1.5的浓缩液,随后文火蒸发至稠高状,烘干并加入常规辅料,制得临 床可接受的颗粒剂;或者,
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶,粉碎并过200目筛;取蜂蜜置于瓷锅中熬制,并加入选定量的鸦胆子油拌匀,加入上述原料粉末混匀,冷却后制得临床可接受的丸剂;或者,
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草、茶叶混匀,加水浸泡后,加热煎煮并收集煎煮液,随后加入选定量的鸦胆子油混匀,固液分离并收集滤液文火浓缩至比重为1.30-1.35的浓缩液,然后加入浓度为0.9%的氯化钠溶液,制得临床可接受的中药针剂。
所述加入的蜂蜜与中药原料药总和的质量配比为(3-6):100。
本发明还公开了一种治疗恶性肿瘤的贴剂,所述贴剂的原料药组成为:
喜树果1-30重量份  鸦胆子油1-30重量份  斑蝥0.1-0.9重量份
狼毒1-30重量份    土贝母1-30重量份    肿节风1-30重量份。
本发明还公开了一种制备所述治疗恶性肿瘤贴剂的方法,包括如下步骤:
S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风,置粉碎机粉碎过200目细筛,备用;
S4、取生石灰投入到装有清水的容器中,反应后得石灰水,待石灰水沉清十五天之后,取出沉清石灰水,装于容器待用,取选定量的鸦胆子油及生山茶油,加入至装有石灰水容器里,搅拌成糊状,最后加入步骤S3制 备的细粉,制得临床可接受的贴剂。
所述步骤S4中加入的生石灰与清水的质量配比为1:5,取出的沉清石灰水与所述山茶油的质量配比为1:1。
本发明所述中药组合物,是在传统中医药理论指导下,并结合现代医学的研究成果,在大量前期试验研究的基础上,精选十七味中药原料重新组方。本发明所述中药组合物,以喜树果、鸦胆子、斑蝥、狼毒为君药,主攻恶毒;以土贝母、肿节风、夏枯草、莪术、黄芪、丹叁、茯苓、三七、桑黄、蒲公英,此十味药为臣药,达到清热解毒逐积,活血化瘀之效;以绞股蓝、甘草、茶叶为佐使药,共奏解毒攻毒、扶正驱邪的功效。其中,
喜树果:味苦、辛、性寒,有抗癌散结、清热解毒、活血消肿的功效,并有抗肿瘤的作用,喜树碱能使癌细胞发生变性、坏死、核固缩、浓染、染色质凝聚,胞浆多空泡等形态学改变,还能使癌细胞和宿主肝细胞超微结构发生变化,最终导致癌细胞溶解破坏而促进细胞死亡;
鸦胆子:味苦、性寒,有清热止痢、解毒杀虫的功效,有抗肿瘤作用,鸦胆子含有大量脂肪酸,特别是不饱和脂肪酸,故有效明显的抗癌作用,鸦胆子苦素、鸦胆子苦烯、鸦胆子苦醇、鸦胆子苷、鸦胆子油等多种不同成分,均有不同程度的抗肿瘤作用,以鸦胆子油作用最为明显,鸦胆子醇、鸦胆子苦醇和鸦胆子苷A、D、E对P388淋巴细胞、白血病DNA聚合酶、RNA聚合酶、胸苷酸合成酶(thymidylatesyn-thetase)、双氢叶酸还原酶、磷酸核糖焦磷酸氨转移酶(phosphoribosyl pyrophosphateaminotransferase)和组织蛋白酶的活性有边缘抑制作用,抑制RNA和蛋白质合成。以鸦胆子苦醇作用最强,并能抑制P388细胞增殖及细胞内已糖激酶,磷酸果糖激酶和琥珀酸脱氢酶的活性。鸭胆子含的黄花菜木脂素A,鸦胆子苦素D、E,鸦胆子苦苷A,鸦胆子苷A、H、F、I、J、L、P,鸦胆子苦醇及去氢鸦胆子醇均显示有抗P388淋巴性白血病活性。鸦胆子苷AB对W256、ECA艾氏腹水癌也有抑制作用;
斑蝥:味辛、性温,有大毒,有攻毒蚀疮,破血散结的功效,有抗肿瘤作用,斑蝥素是斑蝥的活性成份,对肝脏和癌细胞有较强的亲和性、斑蝥素,首先能抑制癌细胞蛋白质合成,继而影响RNA和DNA合成,最终抑制癌细胞的生长和分裂;
狼毒:味苦、辛、性平,有逐水祛痰,破积杀虫的功效,狼毒中的格尼迪木任对多种肿瘤有较强的抑制作用;
土贝母:味苦、性凉,归肺、胃经,有抗癌作用,土贝母糖苷Ⅰ对多种移植性肿瘤有抑制作用,有清热化痰、散结拔毒的功效;
肿节风:味辛苦、性平,有祛风除湿、活血散瘀、清热解毒的功效,肿节风挥发油、浸育对自血病615细胞、TM755、肺腺病615、白发乳腺癌615、自发腹水型AL771、艾氏腹水癌、肉瘤180、肉瘤37、瓦克癌256均有一定的抑制作用;
夏枯草:味苦、辛、性寒,有清肝泻火,解郁散结,消肿解毒的功效,夏枯草所含的熊果酸对细胞P388、L1210和人体肿瘤细胞A-549具有显著细胞毒性,对艾氏腹水瘤及肉瘤S180均有抑制作用;
莪术:味辛、苦、性温,有破血行气,消积止痛的功效,有抗肿瘤的作用,对体外培养的肝癌细胞有较强的杀伤作用,能明显抑制RNA聚合酶活性,使DNA吸收光谱移位及荧光强度增加;
黄芪:味甘、性微温,有补气升阳、固表止汗、行水消肿、托毒生肌的功效,有抗肿瘤的作用,黄芪多糖对癌性腹水淋巴细胞激活有增效作用,服用者癌性腹水中CTL细胞易被IL-2激活,激活时间缩短、扩增倍数大;此外,还对正常人及肿瘤患者外周血单个核细胞在体外分泌TNF具有明显地促进作用,对TNF-a和TNF-b均有增强作用,黄芪能显著增强肺癌浸润淋巴细胞(TIL)的体外杀伤活性,与人参皂苷合用对TIL细胞具有协同正向调节作用;
丹参:味苦、微辛、性微寒,有凉血消肿、活血祛瘀、养血安神的功效,有促进组织修复和再生的作用,丹参酮ⅡA可通过影响癌基因表达及 DNA多聚酶活性,抑制HL-60细胞合成,从而抑制细胞增殖,诱导细胞分化;
茯苓:味甘、淡、性平,有利水渗湿、健脾补中、宁心安神的功效,茯苓多糖对生长迟缓型的移植肿癌具有显著抑制作用,茯苓多糖体的抗肿瘤作用机制主要是增强了机体的免疫功能,激活了免疫监视系统,提高机体对癌细胞特异性抗原的免疫能力,发挥机体的抗癌能力,使被激活的补体通过影响
Figure PCTCN2017113242-appb-000005
淋巴细胞及体液因子等,协同杀伤肿瘤细胞;
三七:味甘、微苦、性温,有止血散瘀、消肿定痛的功效,有抗肿瘤作用,三七中的人参苷Rb1、Rd、Rh1、Rh2均能使培养的肿瘤细胞受到抑制,Rh1直接作用于细胞膜,Rh2能使癌细胞再分化诱导逆转成非癌细胞;
桑黄:味微苦、性寒,有抗癌作用,强化免疫力,诱导癌细胞自行死亡,能抑制癌细胞的增殖及转移;
蒲公英:味苦、甘、性寒,有清热解毒,散结消肿,除湿利尿的功效;
绞股蓝:味甘、性温,有补虚润燥、祛风活血、消肿解毒的功效,有抗肿瘤作用,绞股蓝能防止正常细胞癌化,并促使细胞发挥自我治愈能力,引导癌化细胞恢复正常。绞股蓝对人胃腺癌(SGC-7901)细胞CO照射效应有明显的影响,显示细胞存活比率提高,S期细胞明显增加,G1期、G2期细胞比例减少;绞股蓝中,绞股蓝皂甘X,X可直接杀灭S180内瘤细胞。绞股蓝皂苷XX1在体外显著抑制肝癌细胞生长。绞股蓝皂苷对体外培养的肺癌、子宫癌、黑色素肿瘤细胞有抑制作用。绞股蓝中的人参二醇和原人参二醇有一定抗肿瘤活性,绞股蓝多糖对肿瘤细胞有较强的抑制杀灭作用。绞股蓝抑制肿瘤细胞,增殖和增强免疫功能的作用,主要表现在对肿癌细胞有丝分裂的阻断,干扰DNA合成过程及提高其突变能力。GPS可使环磷酰胺所致的姐妹染色体互换频率增高显著下降。绞股蓝能使直肠腺癌细胞的DNA合成降低,核分裂数减少,细胞变性坏死;
甘草:味甘、性平,有益气补中、缓急止痛、润肺止咳、泻火解毒、调和药性的功效;
茶叶:味苦、甘、性凉,有消利头目,除烦止渴消食化痰、利尿解毒的功效,有抗肿瘤、抗诱变作用,绿茶多酚(GTP)能抑制黄曲霉素B(AFB)和苯丙芘BP等,调节免疫作用,绿茶可改善环磷酰胺所损害的骨髓造血功能,使其白细胞和红细胞数上升,有基因调节的作用。
本发明所述中药组合物,对56例均患有晚期原发性肝癌的确诊患者进行临床实验,治疗效果中症状完全缓解12例、部分缓解20例、稳定22例,总有效率高达为96.4%,表明本发明药物可有效控制肿瘤的生长,抑制癌细胞扩散,同时可改善患者肝区疼痛、身体乏力、食欲不振等症状,从而提高患者生存质量,延长患者生存期。除此之外,本发明药物对肺癌、淋巴癌、胃癌、食道癌、膀胱癌、卵巢癌、前列腺癌、胰腺癌等其它肿瘤病和对已做过手术、放疗、化疗的肿瘤患者的康复治疗同样有理想的治疗效果。
具体实施方式
为了使本发明的目的、技术方案和优点更加清楚,下面将对本发明的实施方式作进一步地详细描述。本发明可以以许多不同的形式实施,而不应该被理解为限于在此阐述的实施例。相反,提供这些实施例,使得本公开将是彻底和完整的,并且将把本发明的构思充分传达给本领域技术人员,本发明将仅由权利要求来限定。
实施例1:
本发明的治疗恶性肿瘤的中药组合物(胶襄剂)
本实施例所述治疗恶性肿瘤的胶囊剂的中药组合物组成:
Figure PCTCN2017113242-appb-000006
Figure PCTCN2017113242-appb-000007
本实施例所述治疗恶性肿瘤的胶囊剂的制备方法,包括如下步骤:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.8g、狼毒片10g,以及喜树果12g、土贝母6g、肿节风6g、夏枯草12g、莪术9g、黄芪9g、丹参8g、茯苓9g、三七10g、桑黄6g、蒲公英12g、绞股蓝15g、甘草6g、茶叶6g,加入500ml水浸泡30分钟后,加热至沸、煎煮90分钟,过滤出煎出液,药渣按上述方法煎出2次,收集各煎出液,加入鸦胆子油12g,搅拌均匀,离心分离后,将分离液文火浓缩至比重为1.30的浓缩液,烘干,按质量比为1:1加β环糊精,制得治疗恶性肿瘤胶囊剂。
实施例2:
本发明的治疗恶性肿瘤的中药组合物(颗粒冲剂)
本实施例所述治疗恶性肿瘤的颗粒剂的中药组合物组成:
Figure PCTCN2017113242-appb-000008
本实施例所述治疗恶性肿瘤的颗粒剂的制备方法,包括如下步骤:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯 米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.5g、狼毒片9g,以及喜树果12g、土贝母12g、肿节风15g、夏枯草9g、莪术9g、黄芪9g、丹参5g、茯苓6g、三七6g、桑黄6g、蒲公英6g、绞股蓝8g、甘草9g、茶叶12g,粉碎成粗颗粒状,置于容器中,加入500ml的水浸泡30分钟后,加热至沸,煎煮90分钟,过滤出煎出液,药渣按上述方法煎出3次,收集各煎出液,加入鸦胆子油12g,文火蒸发至比重为1.0的蒸发液,冷却后加入1.5倍量的60%乙醇充分混匀,放置过夜,次日取上清液(必要时过滤),沉淀物用2倍量的60%乙醇洗涤得洗液,合并洗液和上清液,减压回收乙醇,浓缩至比重为1.2的浓缩液,静置36小时,过滤,文火蒸发至稠高状,烘干,按质量比为1:1加入医用淀粉,制得治疗恶性肿瘤中药颗粒冲剂。
实施例3:
本发明的治疗恶性肿瘤的中药组合物(贴剂)
本实施例的治疗恶性肿瘤贴剂的中药组合物组成:
喜树果12g      鸦胆子油12g      斑蝥(制)0.8g
狼毒(制)12g    土贝母18g        肿节风15g。
本实施例的治疗恶性肿瘤贴剂的制备方法,包括如下步骤:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.8g、狼毒片12g,以及喜树果12g、土贝母18g、肿节风15g,置粉碎机粉碎过200目细筛,筛成细粉待用;
S4、取生石灰投入到装有清水的容器中,所述生石灰与清水的质量比 为1:5,反应后得石灰水,待石灰水沉清十五天之后,取出沉清石灰水12g,装于容器待用,取生山茶油12g、鸦胆子油12g加入置装有石灰水容器里,搅拌成糊状,最后加入步骤S3制备的细粉,制得治疗恶性肿瘤贴剂。
实施例4:
本发明的治疗恶性肿瘤的中药组合物(大蜜丸)
本实施例所述治疗恶性肿瘤的大蜜丸中药组合物组成:
Figure PCTCN2017113242-appb-000009
本实施例所述治疗恶性肿瘤的大蜜丸的制备方法,包括如下步骤:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.6g、狼毒片6g,以及喜树果9g、土贝母9g、肿节风9g、夏枯草12g、莪术6g、黄芪12g、丹参6g、茯苓6g、三七10g、桑黄8g、蒲公英6g、绞股蓝9g、甘草9g、茶叶9g,放于粉碎机粉碎,过200目细筛,筛成粉末备用;
S4、取生蜂蜜6g置于瓷锅中熬至用手粘上能抽2-3厘米的丝为止,加入鸦胆子油9g,拌匀,加入步骤S3制备的粉末,混匀放凉,制得治疗恶性肿瘤口服大蜜丸。
实施例5:
本发明的治疗恶性肿瘤的中药组合物(小蜜丸)
本实施例所述治疗恶性肿瘤的小蜜丸的中药组合物组成:
Figure PCTCN2017113242-appb-000010
本实施例所述治疗恶性肿瘤的小蜜丸的制备方法,包括如下步骤:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.8g、狼毒片6g,以及喜树果10g、土贝母15g、肿节风15g、夏枯草15g、莪术7g、黄芪7g、丹参7g、茯苓7g、三七7g、桑黄7g、蒲公英15g、绞股蓝15g、甘草7g、茶叶7g,放于粉碎机粉碎,过200目细筛,筛成粉末备用;
S4、取生蜂蜜7g置于瓷锅中熬至用手粘上能抽2-3厘米的丝为止,加入鸦胆子油10g,拌匀,加入步骤S3制备的粉末,混匀放凉,制得治疗恶性肿瘤口服小蜜丸。
实施例6:
本发明的治疗恶性肿瘤的中药组合物(水蜜丸)
本实施例所述治疗恶性肿瘤的水蜜丸的中药组合物组成:
Figure PCTCN2017113242-appb-000011
Figure PCTCN2017113242-appb-000012
本实施例所述治疗恶性肿瘤的水蜜丸的制备方法:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.2g、狼毒片4g,以及喜树果4g、土贝母4g、肿节风4g、夏枯草5g、莪术4g、黄芪6g、丹参8g、茯苓12g、三七11g、桑黄4g、蒲公英5g、绞股蓝5g、甘草9g、茶叶9g,放于粉碎机粉碎,过200目细筛,筛成粉末备用;
S4、取生蜂蜜5g置于瓷锅中熬至用手粘上能抽2-3厘米的丝为止,加入鸦胆子油4g,拌匀,加入步骤S3制备的粉末,混匀放凉,制得治疗恶性肿瘤口服水蜜丸。
实施例7:
本发明的治疗恶性肿瘤的中药组合物(针剂)
本实施例所述治疗恶性肿瘤的针剂的中药组合物组成:
Figure PCTCN2017113242-appb-000013
本实施例所述治疗恶性肿瘤的针剂的制备方法:
S1、按质量比1:2取斑蝥与糯米,置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足备用;
S2、取狼毒片,加入0.3倍狼毒片重量的米醋拌匀,闷润至透,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭备用;
S3、取经步骤S1、S2处理后的斑蝥0.5g、狼毒片6g,以及喜树果9g、土贝母9g、肿节风9g、夏枯草9g、莪术12g、黄芪6g、丹参8g、茯苓6g、三七10g、桑黄8g、蒲公英12g、绞股蓝8g、甘草7g、茶叶7g,加入500ml水浸泡30分钟后,加热至沸、煎煮90分钟,过滤出煎出液,药渣按上述方法煎出2次,收集各煎出液,加入鸦胆子油9g,搅拌均匀,离心分离后,将分离液文火浓缩至比重为1.35的浓缩液,然后按照1:1的比例加入浓度为0.9%的氯化钠溶液,搅拌均匀,制得治疗恶性肿瘤中药针剂。
实验例
实验例1对肝癌的治疗效果
一、对肝癌肿瘤细胞株的抑制实验
1、材料
1.1药物:称取喜树果12g、斑蝥(制)0.8g、狼毒片(制)10g、土贝母6g、肿节风6g、夏枯草12g、莪术9g、黄芪9g、丹参8g、茯苓9g、三七10g、桑黄6g、蒲公英12g、绞股蓝15g、甘草6g、茶叶6g,加入500ml水浸泡30分钟后,加热至沸、煎煮90分钟,过滤出煎出液,药渣按上述方法煎出2次,收集各煎出液,加入鸦胆子油12g,搅拌均匀,离心分离后,将分离液文火浓缩至比重为1.30的浓缩液。
1.2动物:KM小鼠,体重20±3g。
1.3瘤株:肝癌HepS22。
2、实验方法
取荷瘤传代鼠脱颈椎处死,切开皮肤,选择肿瘤生长良好、无坏死或 液化的癌组织,按1:3加入无菌生理盐水,用组织匀浆器制成癌细胞悬液,在实验小鼠腋窝皮下接种0.2ml。接种后次日随机分组,每组12只。
实验设高、中、低剂量给药三个实验组、模型组和对照组。
其中高剂量实验组给药量为1g/kg体重,中剂量实验组给药量为0.5g/kg体重,低剂量实验组给药量为0.1g/kg体重。
对照组给环磷酰胺20mg/kg体重。
模型组给无菌生理盐水1g/kg体重。
灌胃给药,每天一次,给药10天后处死。
称体重,摘瘤,称重,计算抑瘤率,计算公式如下:
抑瘤率(100%)=(1-给药组平均瘤重/模型组平均瘤重)×100%。
3、统计学方法
数据采用SPSS17.0软件进行统计分析,计量资料以X±S表示,治疗前后指标比较采用t检验;计数资料采用X2检验。P<0.05表示差异具有统计学意义。
4、实验结果
表1:本发明药物对HepS22实体瘤的实验结果
给药各组 小鼠数 平均瘤重(g)X±SD 肿瘤抑制率(100%)
模型组 12 3.14±0.16 -
对照组 12 1.57±0.21 50.00
高剂量组 12 1.44±0.28 54.14
中剂量组 12 1.56±0.32 50.32
低剂量组 12 1.68±0.44 46.50
与模型组比较:P<0.05;与对照组比较:P<0.05
实验结果表明:本发明中药组合物对小鼠实验性肝肿瘤有明显的抑制作用。本发明中药组合物高剂量组的抑瘤率明显高于西药环磷酰胺对照组, 且具有显著性差异。
二、中药组合物临床实验:
在2014年1月至2016年12月期间对87例原发性肝癌患者治疗的临床实验报告如下:
1、一般资料
本次研究选取的56例患者均为晚期原发性肝癌的确诊患者,全部符合《临床诊疗指南》中与原发性肝癌的相关的诊断标准。56例患者中男33例,女23例,平均年龄44岁。
临床分期:Ⅱ期35例,Ⅲ期21例。
2、治疗方法
患者服用本发明实施例1制得的胶囊剂,每次2粒,每日3次,1个月为一疗程,连续服用3个疗程。
3、疗效判断标准:
完全缓解:肿瘤组织完全消失,血清甲胎蛋白恢复至正常范围;
部分缓解:肿瘤组织缩小50%以上,血清甲胎蛋白恢复至正常范围;
稳定:肿瘤组织缩小或增大均不足25%;
恶化:肿瘤组织增大大于20%。
4、实验结果:
临床症状改善:肝区疼痛改善率为82.5%,疲乏无力改善率为76.9%,食欲不振改善率为83.2%。
治疗效果:完全缓解12例,占总病例数的21.4%;部分缓解20例,占总病例数的35.7%;稳定22例,占总病例数的39.3%;恶化2例,占总病例数的3.6%。总有效率为96.4%。
实验结果表明:本发明中药组合物可有效控制肿瘤的生长,抑制癌细胞扩散,同时可改善患者肝区疼痛、身体乏力、食欲不振等症状,从而提 高患者生存质量,延长患者生存期。
除肝癌外,本发明药物对肺癌、淋巴癌、胃癌、食道癌、膀胱癌、卵巢癌、前列腺癌、胰腺癌等其它肿瘤病和对已做过手术、放疗、化疗的肿瘤患者的康复治疗同样有理想的治疗效果。
其它肿瘤临床治疗效果统一评价标准:
临床治愈:原有症状消失;
显效:原有症状比分消失;
好转:原有病情有所减轻;
无效:症状体征无变化。
实验例2
使用本发明实施例1制备的胶囊剂治疗32例患有胃癌的病患3-6个疗程后,观察所述32例患有胃癌的患者的治疗效果,其中治愈18例,显效8例,好转5例,无效1例,总有效率为96.9%。
实验例3
使用本发明实施例2制备的颗粒冲剂治疗29例患有肺癌的病患3-5个疗程后,观察所述29例患有肺癌的患者的治疗效果,其中治愈22例,显效5例,好转1例,无效1例,总有效率为95.5%。
实验例4
使用本发明实施例2制备的颗粒冲剂治疗25例患有膀胱癌的病患3-5个疗程后,观察所述25例患有膀胱癌的患者的治疗效果,其中治愈14例,显效6例,好转3例,无效2例,总有效率为92.0%。
实验例5
使用本发明实施例2制备的颗粒冲剂治疗18例患有卵巢癌的病患3-5个疗程后,观察所述18例患有卵巢癌的患者的治疗效果,其中治愈11例,显效3例,好转3例,无效1例,总有效率为94.4%。
实验例6
使用本发明实施例3制备的贴剂治疗16例患有前列腺癌的病患3-5个疗程后,观察所述16例患有前列腺癌的患者的治疗效果,其中治愈10例,显效2例,好转4例,无效0例,总有效率为100%。
实验例7
使用本发明实施例4制备的口服大蜜丸治疗30例患有食道癌的病患3-6个疗程后,观察所述30例患有食道癌的患者的治疗效果,其中治愈8例,显效7例,好转3例,无效2例,总有效率为93.3%。
实验例8
使用本发明实施例7制备的中药复方针剂治疗23例患有淋巴癌的病患3-6个疗程后,观察所述23例患有淋巴癌的患者的治疗效果,其中治愈14例,显效4例,好转3例,无效2例,总有效率为91.1%。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明的保护范围之中。

Claims (10)

  1. 一种治疗恶性肿瘤的中药组合物,其特征在于,所述中药组合物的原料药组成为:
    Figure PCTCN2017113242-appb-100001
  2. 根据权利要求1所述治疗恶性肿瘤的中药组合物,其特征在于,所述中药组合物的原料药组成为:
    Figure PCTCN2017113242-appb-100002
  3. 根据权利要求1或2所述治疗恶性肿瘤的中药组合物,其特征在于,所述中药组合物的原料药组成为:
    Figure PCTCN2017113242-appb-100003
    Figure PCTCN2017113242-appb-100004
  4. 由权利要求1-3任一项所述的治疗恶性肿瘤的中药组合物,添加常规辅料,按照常规工艺制备成的临床可接受的制剂。
  5. 根据权利要求4所述的制剂,其特征在于,包括胶囊剂、颗粒剂、贴剂、针剂、合剂或丸剂。
  6. 一种制备权利要求4或5所述制剂的方法,其特征在于,包括取选定量的喜树果、鸦胆子油、斑蝥、狼毒、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀的步骤,并添加常规辅料,按照常规工艺制成的临床可接受的制剂。
  7. 根据权利要求6所述的制备所述制剂的方法,其特征在于,包括如下步骤:
    S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
    S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、鸦胆子油、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,添加常规辅料,按照常规工艺制成的临床可接受的制剂。
  8. 根据权利要求7所述的制备所述制剂的方法,其特征在于,包括如下步骤:
    S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
    S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,加水浸泡后,加热至沸腾并煎煮,取煎煮液加入选定量的鸦胆子油混匀,固液分离后,收集滤液文火浓缩至比重为1.30-1.35的浓缩液,烘干并加入常规辅料,制得临床可接受的胶囊剂;或者,
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶混匀,粉碎成粗颗粒状,加水浸泡后,加热煎煮并收集煎煮液,随后加入选定量的鸦胆子油,文火蒸发至比重为0.9-1.1的蒸发液,冷却后加入60wt%乙醇充分混匀沉降,取上清液并减压回收乙醇,浓缩至比重为1.2-1.5的浓缩液,随后文火蒸发至稠高状,烘干并加入常规辅料,制得临床可接受的颗粒剂;或者,
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草和茶叶,粉碎并过200目筛;取蜂蜜置于瓷锅中熬制,并加入选定量的鸦胆子油拌匀,加入上述原料粉末混匀,冷却后制得临床可接受的丸剂;或者,
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风、夏枯草、莪术、黄芪、丹参、茯苓、三七、桑黄、蒲公英、绞股蓝、甘草、茶叶混匀,加水浸泡后,加热煎煮并收集煎煮液,随后加入选定量的鸦胆子油混匀,固液分离并收集滤液文火浓缩至比重为1.30-1.35的浓缩液,然后加入浓度为0.9%的氯化钠溶液,制得临床可接受的中药针剂。
  9. 一种治疗恶性肿瘤的贴剂,其特征在于,所述贴剂的原料药组成为:
    喜树果1-30重量份  鸦胆子油1-30重量份  斑蝥0.1-0.9重量份
    狼毒1-30重量份    土贝母1-30重量份    肿节风1-30重量份。
  10. 一种制备权利要求9所述治疗恶性肿瘤贴剂的方法,其特征在于,包括如下步骤:
    S1、取选定量的斑蝥与糯米置热锅内,用文火加热,拌炒至糯米呈黄棕色,取出,除去糯米、放凉,将斑蝥去头、去翅、去足,备用;
    S2、取选定量的狼毒片,加米醋拌匀,置锅内,用文火炒干,取出放凉,贮干燥容器内密闭,备用;
    S3、取处理后的斑蝥、狼毒片,以及选定量的喜树果、土贝母、肿节风,置粉碎机粉碎过200目细筛,备用;
    S4、取生石灰投入到装有清水的容器中,反应后得石灰水,待石灰水沉清十五天之后,取出沉清石灰水,装于容器待用,取选定量的鸦胆子油及生山茶油,加入至装有石灰水容器里,搅拌成糊状,最后加入步骤S3制备的细粉,制得临床可接受的贴剂。
PCT/CN2017/113242 2017-06-23 2017-11-28 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂 WO2018233213A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710489050.4A CN107261061B (zh) 2017-06-23 2017-06-23 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂
CN201710489050.4 2017-06-23

Publications (1)

Publication Number Publication Date
WO2018233213A1 true WO2018233213A1 (zh) 2018-12-27

Family

ID=60069560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/113242 WO2018233213A1 (zh) 2017-06-23 2017-11-28 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂

Country Status (4)

Country Link
CN (1) CN107261061B (zh)
HK (1) HK1247513A2 (zh)
TW (1) TW201904594A (zh)
WO (1) WO2018233213A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107261061B (zh) * 2017-06-23 2018-06-19 邓圣平 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂
CN115414353A (zh) * 2022-06-02 2022-12-02 宁夏医科大学 鸦胆子苦素D抑制TNF-α作用下CAFs促三阴性乳腺癌转移的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107261061A (zh) * 2017-06-23 2017-10-20 邓圣平 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1132603C (zh) * 2000-08-03 2003-12-31 尹秀平 复方斑蝥胶囊

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107261061A (zh) * 2017-06-23 2017-10-20 邓圣平 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIN, PENGFEI ET AL.: "Research development of Bolbostemma Paniculatum (Maxim) Franquet", JOURNAL OF SHENYANG PHARMACEUTICAL UNIVERSITY, vol. 20, no. 2, 31 March 2003 (2003-03-31), pages 152 - 156 *
QIN, JUNZHE ET AL.: "New progress in the study of functional components of Phellinus Ignarius (non-official translation)", EDIBLE FUNGI, no. 5, 23 September 2008 (2008-09-23), pages 1 - 2 *
WANG, JIMIN ET AL.: "Precaution against recurrence and metastasis after radiotherapy for cancer patients with compound gynostemma pentaphyllum soup (non-official translation)", HEBEI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 19, no. 1, 27 January 1997 (1997-01-27), pages 22 - 23 *
WU, YONGFANG: "Application of traditional Chinese medicine in cancer treatment (non-official translation)", NEW CHINESE MEDICINE, vol. 9, no. 1, 1 January 1978 (1978-01-01), pages 35 - 40 *

Also Published As

Publication number Publication date
CN107261061A (zh) 2017-10-20
HK1247513A2 (zh) 2018-09-21
TW201904594A (zh) 2019-02-01
CN107261061B (zh) 2018-06-19

Similar Documents

Publication Publication Date Title
CN100490789C (zh) 一种治疗癌症的中药肠溶胶囊剂的用途
CN103893722A (zh) 一种治疗日光性皮炎的中药组合物及其制备方法
CN101716318B (zh) 一种用于辅助化疗方式治疗消化系统肿瘤的中药制剂
CN103768398A (zh) 一种治疗晚期肺肿瘤的中药组合物
CN102688317B (zh) 用于治疗肝癌的中药
WO2018233213A1 (zh) 一种治疗恶性肿瘤的中药组合物、制备方法及其制剂
CN106668780A (zh) 一种治疗肿瘤的中药组合物
CN104998197A (zh) 一种用于治疗肝癌的中药组合物
WO2017152834A1 (zh) 一种雪柳叶层孔菌及其在制备药物中的用途
CN104800764A (zh) 治疗肝癌的中药剂及制法
CN101693096A (zh) 一种治疗肝癌的药物及其制备方法
CN108324916A (zh) 治疗肿瘤的中药及其制备方法
CN103520337A (zh) 一种治疗肝癌的中药组方
CN114452369B (zh) 一种治疗乳腺癌的中药组合物
CN113952435B (zh) 一种辅助治疗肝癌的中药组合物及其制备方法
WO2004084924A1 (fr) Composition pharmaceutique pour le traitement de l'hypertrophie benigne de la prostate et mode de preparation
CN105663551A (zh) 胰腺癌患者术后服用的中药制剂及制法
CN106237206A (zh) 一种治疗肿瘤的中药制剂及其制备方法
CN105853923A (zh) 一种治疗早期宫颈癌的纯中药制剂
CN104689246B (zh) 一种治疗胃癌的药物
CN114869987A (zh) 一种用于预防和治疗肝癌的中药组合物
CN116459324A (zh) 一种治疗癌因性肝阳虚型抑郁的新中药贴剂及其制备方法
CN108096507A (zh) 一种治疗脑肿瘤及脑囊肿的中药组合物及制备方法
CN100336555C (zh) 一种抗肿瘤的参丹胶囊及其制备工艺
CN110522881A (zh) 一种防治脂肪瘤中药组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17915043

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17915043

Country of ref document: EP

Kind code of ref document: A1